 |
|
N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP), Cardiovascular Events, and Mortality in Patients With Stable Coronary Heart Disease
Kirsten Bibbins-Domingo, PhD, MD;
Reena Gupta, MD;
Beeya Na, MPH;
Alan H. B. Wu, PhD;
Nelson B. Schiller, MD;
Mary A. Whooley, MD
JAMA. 2007;297:169-176.
Context Identification of individuals at high risk for cardiovascular events is important for the optimal use of primary and secondary prevention measures.
Objective To determine whether plasma levels of amino terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) predict cardiovascular events or death independent of other available prognostic tests.
Design, Setting, and Participants Prospective cohort study (2000-2002) of 987 individuals in California with stable coronary heart disease in the Heart and Soul Study, who were followed up for a mean of 3.7 (range, 0.1-5.3) years.
Main Outcome Measures The association of baseline NT-proBNP levels with death or cardiovascular events (myocardial infarction, stroke, or heart failure). Traditional clinical risk factors, echocardiographic measures, ischemia, other biomarkers, and New York Heart Association classification were adjusted for to determine whether NT-proBNP levels were independent of other prognostic factors. Receiver operating characteristic (ROC) curves were used to assess the incremental prognostic value of adding NT-proBNP level to these other measures.
Results A total of 256 participants (26.2%) had a cardiovascular event or died. Each increasing quartile of NT-proBNP level (range of quartile 1, 8.06-73.95 pg/mL; quartile 2, 74-174.5 pg/mL; quartile 3, 175.1-459 pg/mL; quartile 4,  460 pg/mL) was associated with a greater risk of cardiovascular events or death, ranging from 23 of 247 (annual event rate, 2.6%) in the lowest quartile to 134 of 246 (annual event rate, 19.6%) in the highest quartile (unadjusted hazard ratio [HR] for quartile 4 vs quartile 1, 7.8; 95% confidence interval [CI], 5.0-12.1; P<.001). Each SD increase in log NT-proBNP level (1.3 pg/mL) was associated with a 2.3-fold increased rate of adverse cardiovascular outcomes (unadjusted HR, 2.3; 95% CI, 2.0-2.6; P<.001), and this association persisted after adjustment for all of the other prognostic measures (adjusted HR, 1.7; 95% CI, 1.3-2.2; P<.001). The addition of NT-proBNP level to standard clinical assessment and complete echocardiographic parameters significantly improved the area under the ROC curves for predicting subsequent adverse cardiovascular outcomes (0.80 for clinical risk factors and echocardiographic parameters plus log NT-proBNP vs 0.76 for clinical risk factors and echocardiographic parameters only; P = .006).
Conclusions Elevated levels of NT-proBNP predict cardiovascular morbidity and mortality, independent of other prognostic markers, and identify at-risk individuals even in the absence of systolic or diastolic dysfunction by echocardiography. Level of NT-proBNP may help guide risk stratification of high-risk individuals, such as those with coronary heart disease.
Author Affiliations: Departments of Medicine (Drs Bibbins-Domingo, Gupta, Schiller, and Whooley), Epidemiology and Biostatistics (Drs Bibbins-Domingo and Whooley), and Laboratory Medicine (Dr Wu), University of California, San Francisco; Division of General Internal Medicine, San Francisco General Hospital (Drs Bibbins-Domingo, Gupta, and Wu); and San Francisco Veterans Administration Medical Center (Ms Na and Drs Schiller and Whooley).
RELATED ARTICLE
Natriuretic Peptides and Cardiovascular Events: More Than a Stretch
Marvin A. Konstam
JAMA. 2007;297(2):212-214.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients
Bankier et al.
Eur Heart J 2008;29:2212-2217.
ABSTRACT
| FULL TEXT
Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients
Winkler et al.
Eur Heart J 2008;29:2092-2099.
ABSTRACT
| FULL TEXT
Plasma B-type natriuretic peptide levels reflect the presence and severity of stable coronary artery disease in chronic haemodialysis patients
Niizuma et al.
Nephrol Dial Transplant 2008;0:gfn491v1-gfn491.
ABSTRACT
| FULL TEXT
Minimally Elevated Cardiac Troponin T and Elevated N-Terminal Pro-B-Type Natriuretic Peptide Predict Mortality in Older Adults: Results From the Rancho Bernardo Study
Daniels et al.
J Am Coll Cardiol 2008;52:450-459.
ABSTRACT
| FULL TEXT
Inducible Ischemia and the Risk of Recurrent Cardiovascular Events in Outpatients With Stable Coronary Heart Disease: The Heart and Soul Study
Gehi et al.
Arch Intern Med 2008;168:1423-1428.
ABSTRACT
| FULL TEXT
Screening and Assessment of Coronary Heart Disease in HIV-Infected Patients
Hsue et al.
Circulation 2008;118:e41-e47.
FULL TEXT
B-type natriuretic peptide: a treatment, not a diagnostic marker
Yip
Heart 2008;94:542-544.
FULL TEXT
Developing the utility of blood biomarker associations beyond population sample linkage to events in cardiovascular patients
MacFadyen and Ng Kam Chuen
Eur Heart J 2008;29:837-839.
FULL TEXT
N-Terminal Prohormone Brain Natriuretic Peptide as a Predictor of Cardiovascular Disease and Mortality in Blacks With Hypertensive Kidney Disease: The African American Study of Kidney Disease and Hypertension (AASK)
Astor et al.
Circulation 2008;117:1685-1692.
ABSTRACT
| FULL TEXT
Predictive Value of Brain Natriuretic Peptides in Patients on Peritoneal Dialysis: Results from the ADEMEX Trial
Paniagua et al.
CJASN 2008;3:407-415.
ABSTRACT
| FULL TEXT
New cardiovascular risk factors exist, but are they clinically useful?
Wang
Eur Heart J 2008;29:441-444.
ABSTRACT
| FULL TEXT
Natriuretic Peptides
Daniels and Maisel
J Am Coll Cardiol 2007;50:2357-2368.
ABSTRACT
| FULL TEXT
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure
Wilson Tang et al.
Circulation 2007;116:e99-e109.
FULL TEXT
The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney
Struthers and Lang
Eur Heart J 2007;28:1678-1682.
ABSTRACT
| FULL TEXT
Glomerular Filtration Rate and N-Terminal Pro-Brain Natriuretic Peptide as Predictors of Cardiovascular Mortality in Vascular Patients
Shadman et al.
J Am Coll Cardiol 2007;49:2172-2181.
ABSTRACT
| FULL TEXT
NT-proBNP Testing: Any Value in Stable CHD?
Journal Watch Cardiology 2007;2007:1-1.
FULL TEXT
Predictive Value of Natriuretic Peptide in Coronary Heart Disease
JWatch General 2007;2007:3-3.
FULL TEXT
Natriuretic Peptides and Cardiovascular Events: More Than a Stretch
Konstam
JAMA 2007;297:212-214.
FULL TEXT
|
